The Intravenous Ketamine Test Predicts Subsequent Response to an Oral Dextromethorphan Treatment Regimen in Fibromyalgia Patients

Steven Cohen, Michael H. Verdolin, Audrey S. Chang, Connie Kurihara, Bennie J. Morlando, Jianren Mao

Research output: Contribution to journalArticle

Abstract

Fibromyalgia (FM) is a challenging pain syndrome for which no reliable pharmacologic treatment exists. Recent clinical studies suggest that N-methyl-D-aspartate receptors might play a role in the pathogenesis of this disorder. To determine whether an intravenous (IV) ketamine test predicts the response to a therapeutic trial with an oral N-methyl-D-aspartate receptor antagonist, we performed a low-dose (0.1 mg/kg) IV ketamine infusion on 34 consecutive patients with FM, which was subsequently followed by an oral dextromethorphan (DX) treatment regimen. As per previous guidelines, the cutoff value for a positive response to the IV ketamine test was designated to be 67% pain relief, and a positive response to DX treatment was 50% pain reduction at 4- to 6-week follow-up visits. The degree of correlation between pain relief with ketamine and DX was highly significant (Pearson correlation coefficient, 0.66; P <.001). Ten patients responded positively to both ketamine and DX, 19 responded to neither drug, 3 had a positive response to ketamine but not DX, and 2 obtained good pain relief with DX but not ketamine. The sensitivity of the IV ketamine test was 83%, the specificity was 86%, the positive predictive value was 77%, and the negative predictive value was 91%. An association was also found between the development of side effects to the two treatments. Perspective: The response to an IV ketamine infusion was found to predict the subsequent response to an oral dextromethorphan treatment regimen in fibromyalgia patients, with an observed agreement of 83%. Considering the refractory nature of fibromyalgia to conventional pain treatments, the IV ketamine test might enhance patient care by saving time and reducing unnecessary treatment trials.

Original languageEnglish (US)
Pages (from-to)391-398
Number of pages8
JournalJournal of Pain
Volume7
Issue number6
DOIs
StatePublished - Jun 2006

Fingerprint

Dextromethorphan
Fibromyalgia
Ketamine
Pain
Therapeutics
N-Methyl-D-Aspartate Receptors
Intravenous Infusions
Patient Care
Guidelines

Keywords

  • Dextromethorphan
  • fibromyalgia
  • intravenous infusion test
  • ketamine
  • N-methyl-D-aspartate receptor antagonist

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Clinical Neurology
  • Neurology
  • Nursing(all)

Cite this

The Intravenous Ketamine Test Predicts Subsequent Response to an Oral Dextromethorphan Treatment Regimen in Fibromyalgia Patients. / Cohen, Steven; Verdolin, Michael H.; Chang, Audrey S.; Kurihara, Connie; Morlando, Bennie J.; Mao, Jianren.

In: Journal of Pain, Vol. 7, No. 6, 06.2006, p. 391-398.

Research output: Contribution to journalArticle

Cohen, Steven ; Verdolin, Michael H. ; Chang, Audrey S. ; Kurihara, Connie ; Morlando, Bennie J. ; Mao, Jianren. / The Intravenous Ketamine Test Predicts Subsequent Response to an Oral Dextromethorphan Treatment Regimen in Fibromyalgia Patients. In: Journal of Pain. 2006 ; Vol. 7, No. 6. pp. 391-398.
@article{1c19a1fd71644f3096fa625119eeced1,
title = "The Intravenous Ketamine Test Predicts Subsequent Response to an Oral Dextromethorphan Treatment Regimen in Fibromyalgia Patients",
abstract = "Fibromyalgia (FM) is a challenging pain syndrome for which no reliable pharmacologic treatment exists. Recent clinical studies suggest that N-methyl-D-aspartate receptors might play a role in the pathogenesis of this disorder. To determine whether an intravenous (IV) ketamine test predicts the response to a therapeutic trial with an oral N-methyl-D-aspartate receptor antagonist, we performed a low-dose (0.1 mg/kg) IV ketamine infusion on 34 consecutive patients with FM, which was subsequently followed by an oral dextromethorphan (DX) treatment regimen. As per previous guidelines, the cutoff value for a positive response to the IV ketamine test was designated to be 67{\%} pain relief, and a positive response to DX treatment was 50{\%} pain reduction at 4- to 6-week follow-up visits. The degree of correlation between pain relief with ketamine and DX was highly significant (Pearson correlation coefficient, 0.66; P <.001). Ten patients responded positively to both ketamine and DX, 19 responded to neither drug, 3 had a positive response to ketamine but not DX, and 2 obtained good pain relief with DX but not ketamine. The sensitivity of the IV ketamine test was 83{\%}, the specificity was 86{\%}, the positive predictive value was 77{\%}, and the negative predictive value was 91{\%}. An association was also found between the development of side effects to the two treatments. Perspective: The response to an IV ketamine infusion was found to predict the subsequent response to an oral dextromethorphan treatment regimen in fibromyalgia patients, with an observed agreement of 83{\%}. Considering the refractory nature of fibromyalgia to conventional pain treatments, the IV ketamine test might enhance patient care by saving time and reducing unnecessary treatment trials.",
keywords = "Dextromethorphan, fibromyalgia, intravenous infusion test, ketamine, N-methyl-D-aspartate receptor antagonist",
author = "Steven Cohen and Verdolin, {Michael H.} and Chang, {Audrey S.} and Connie Kurihara and Morlando, {Bennie J.} and Jianren Mao",
year = "2006",
month = "6",
doi = "10.1016/j.jpain.2005.12.010",
language = "English (US)",
volume = "7",
pages = "391--398",
journal = "Journal of Pain",
issn = "1526-5900",
publisher = "Churchill Livingstone",
number = "6",

}

TY - JOUR

T1 - The Intravenous Ketamine Test Predicts Subsequent Response to an Oral Dextromethorphan Treatment Regimen in Fibromyalgia Patients

AU - Cohen, Steven

AU - Verdolin, Michael H.

AU - Chang, Audrey S.

AU - Kurihara, Connie

AU - Morlando, Bennie J.

AU - Mao, Jianren

PY - 2006/6

Y1 - 2006/6

N2 - Fibromyalgia (FM) is a challenging pain syndrome for which no reliable pharmacologic treatment exists. Recent clinical studies suggest that N-methyl-D-aspartate receptors might play a role in the pathogenesis of this disorder. To determine whether an intravenous (IV) ketamine test predicts the response to a therapeutic trial with an oral N-methyl-D-aspartate receptor antagonist, we performed a low-dose (0.1 mg/kg) IV ketamine infusion on 34 consecutive patients with FM, which was subsequently followed by an oral dextromethorphan (DX) treatment regimen. As per previous guidelines, the cutoff value for a positive response to the IV ketamine test was designated to be 67% pain relief, and a positive response to DX treatment was 50% pain reduction at 4- to 6-week follow-up visits. The degree of correlation between pain relief with ketamine and DX was highly significant (Pearson correlation coefficient, 0.66; P <.001). Ten patients responded positively to both ketamine and DX, 19 responded to neither drug, 3 had a positive response to ketamine but not DX, and 2 obtained good pain relief with DX but not ketamine. The sensitivity of the IV ketamine test was 83%, the specificity was 86%, the positive predictive value was 77%, and the negative predictive value was 91%. An association was also found between the development of side effects to the two treatments. Perspective: The response to an IV ketamine infusion was found to predict the subsequent response to an oral dextromethorphan treatment regimen in fibromyalgia patients, with an observed agreement of 83%. Considering the refractory nature of fibromyalgia to conventional pain treatments, the IV ketamine test might enhance patient care by saving time and reducing unnecessary treatment trials.

AB - Fibromyalgia (FM) is a challenging pain syndrome for which no reliable pharmacologic treatment exists. Recent clinical studies suggest that N-methyl-D-aspartate receptors might play a role in the pathogenesis of this disorder. To determine whether an intravenous (IV) ketamine test predicts the response to a therapeutic trial with an oral N-methyl-D-aspartate receptor antagonist, we performed a low-dose (0.1 mg/kg) IV ketamine infusion on 34 consecutive patients with FM, which was subsequently followed by an oral dextromethorphan (DX) treatment regimen. As per previous guidelines, the cutoff value for a positive response to the IV ketamine test was designated to be 67% pain relief, and a positive response to DX treatment was 50% pain reduction at 4- to 6-week follow-up visits. The degree of correlation between pain relief with ketamine and DX was highly significant (Pearson correlation coefficient, 0.66; P <.001). Ten patients responded positively to both ketamine and DX, 19 responded to neither drug, 3 had a positive response to ketamine but not DX, and 2 obtained good pain relief with DX but not ketamine. The sensitivity of the IV ketamine test was 83%, the specificity was 86%, the positive predictive value was 77%, and the negative predictive value was 91%. An association was also found between the development of side effects to the two treatments. Perspective: The response to an IV ketamine infusion was found to predict the subsequent response to an oral dextromethorphan treatment regimen in fibromyalgia patients, with an observed agreement of 83%. Considering the refractory nature of fibromyalgia to conventional pain treatments, the IV ketamine test might enhance patient care by saving time and reducing unnecessary treatment trials.

KW - Dextromethorphan

KW - fibromyalgia

KW - intravenous infusion test

KW - ketamine

KW - N-methyl-D-aspartate receptor antagonist

UR - http://www.scopus.com/inward/record.url?scp=33746410199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746410199&partnerID=8YFLogxK

U2 - 10.1016/j.jpain.2005.12.010

DO - 10.1016/j.jpain.2005.12.010

M3 - Article

C2 - 16750795

AN - SCOPUS:33746410199

VL - 7

SP - 391

EP - 398

JO - Journal of Pain

JF - Journal of Pain

SN - 1526-5900

IS - 6

ER -